SCHEMBL6673889

SCHEMBL6673889

COc1ccc(NS(=O)(=O)c2c(F)c(F)c(Cl)c(F)c2F)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.58
SMN1; SMN2 Q16637 6/20 0.58
HTT P42858 4/20 0.58
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
ALDH1A1 P00352 4/20 0.57
PKM P14618 2/20 0.57
TSHR P16473 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
THRB P10828 2/20 0.51
MAPT P10636 1/20 0.51
ALOX15 P16050 2/20 0.50
MAPK1 P28482 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
HPGD P15428 1/20 0.49
GAA P10253 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SHMT2 P34897 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087608 0.91 SMN1; SMN2 (0.65) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6676868 0.90 LMNA (0.56) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6675555 0.88 LMNA (0.48) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6677326 0.86 LMNA (0.58) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6677831 0.85 LMNA (0.56) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6086804 0.84 MEN1 (0.62) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6681299 0.84 SMN1; SMN2 (0.56) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6674740 0.83 SMN1; SMN2 (0.55) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6675427 0.83 LMNA (0.50) LMNASMN1; SMN2HTTMEN1KMT2A
SCHEMBL6675713 0.83 LMNA (0.57) LMNASMN1; SMN2HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed
EP-1005453-B1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE LOWERING AGENTS TULARIK INC (US) 2004-10-27 EP disclosed
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US disclosed
US-6284923-B1 BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS TULARIK INC 2001-09-04 US disclosed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP disclosed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 LMNA 2006/4885SMN1; SMN2 4446/4885HTT 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.